KRTAP25-1: A Potential Drug Target and Biomarker (G100131902)

Target Name: KRTAP25-1

NCBI ID: G100131902

KRTAP25-1

Other Name(s): Keratin associated protein 25-1 | keratin associated protein 25-1 | KR251_HUMAN | KAP25.1 | Keratin-associated protein 25-1

KRTAP25-1: A Potential Drug Target and Biomarker

Kallikrein-related peptidases (KRTAPs) are a family of transmembrane proteins that regulate various cellular processes, including cell signaling, migration, and inflammation. The KRTAP25 family, which includes KRTAP25-1, plays a crucial role in these processes, and its function is highly conserved across various species. This conserved function has made KRTAP25-1 an attractive drug target and a potential biomarker for various diseases.

The KRTAP25 family consists of four isoforms, KRTAP25-1, KRTAP25-2, KRTAP25-3, and KRTAP25-4, which differ in their cytoplasmic localization, half-life, and expression level. KRTAP25-1 is the most abundant isoform and is widely expressed in various tissues and organs, including cardiac, skeletal, and nervous muscles, as well as the liver and kidney. It is also involved in the regulation of angiogenesis, inflammation, and cellular signaling.

KRTAP25-1 functions as a potent protein kinase, which regulates various cellular signaling pathways. It has been shown to play a role in the regulation of cell proliferation, differentiation, migration, and survival. KRTAP25-1 has also been shown to be involved in the regulation of cytokine signaling, which is critical for the regulation of cellular immune responses and inflammation.

In addition to its role in cellular signaling, KRTAP25-1 has also been shown to be involved in the regulation of inflammation. It has been shown to play a role in the regulation of neuroinflammation, which is the inflammation caused by various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

KRTAP25-1 has also been shown to be involved in the regulation of fibrosis, which is the excessive growth and progression of connective tissue tissues, such as tendons, ligaments, and heart valves. This process can lead to the development of various diseases, including chronic pain, cancer, and autoimmune diseases.

The potential drug target for KRTAP25-1 is the inhibition of its activity, which can be achieved by small molecules, antibodies, or other therapeutic agents. The inhibition of KRTAP25-1 activity has been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In conclusion, KRTAP25-1 is a highly conserved protein that plays a crucial role in various cellular processes, including cell signaling, inflammation, and fibrosis. Its potential as a drug target makes it an attractive target for the development of new therapeutic agents for the treatment of various diseases. Further research is needed to fully understand the function of KRTAP25-1 and its potential as a drug target.

Protein Name: Keratin Associated Protein 25-1

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins (By similarity)

The "KRTAP25-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP25-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets